癌症免疫治疗中针对武装细胞毒性淋巴细胞的重组抗体。
Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.
作者信息
Koch Joachim, Tesar Michael
机构信息
Affimed GmbH, Technologiepark, Heidelberg, Germany.
出版信息
Transfus Med Hemother. 2017 Sep;44(5):337-350. doi: 10.1159/000479981. Epub 2017 Sep 11.
Abstract
Immunotherapy has the potential to support and expand the body's own armamentarium of immune effector functions, which have been circumvented during malignant transformation and establishment of cancer and is presently considered to be the most promising treatment option for cancer patients. Recombinant antibody technologies have led to a multitude of novel antibody formats, which are in clinical development and hold great promise for future therapies. Among these formats, bispecific antibodies are extremely versatile due to their high efficacy to recruit and activate anti-tumoral immune effector cells, their excellent safety profile, and the opportunity for use in combination with cellular therapies. This review article summarizes the latest developments in cancer immunotherapy using immuno-engagers for recruiting T cells and NK cells to the tumor site. In addition to antibody formats, malignant cell targets, and immune cell targets, opportunities for combination therapies, including check point inhibitors, cytokines and adoptive transfer of immune cells, will be summarized and discussed.
摘要
免疫疗法有潜力支持并扩展人体自身的免疫效应功能武器库，这些功能在恶性转化和癌症形成过程中被规避，目前被认为是癌症患者最有前景的治疗选择。重组抗体技术已产生了多种新型抗体形式，它们正处于临床开发阶段，对未来治疗极具前景。在这些形式中，双特异性抗体极其通用，因为它们在招募和激活抗肿瘤免疫效应细胞方面具有高效性、具有出色的安全性，并且有机会与细胞疗法联合使用。这篇综述文章总结了使用免疫衔接器将T细胞和NK细胞募集到肿瘤部位的癌症免疫疗法的最新进展。除了抗体形式、恶性细胞靶点和免疫细胞靶点外，还将总结和讨论联合疗法的机会，包括检查点抑制剂、细胞因子和免疫细胞的过继转移。
相似文献
1
Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.癌症免疫治疗中针对武装细胞毒性淋巴细胞的重组抗体。
Transfus Med Hemother. 2017 Sep;44(5):337-350. doi: 10.1159/000479981. Epub 2017 Sep 11.
2
Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity.定向优化细胞杀伤（ROCK）：一种高多功能性、多特异性、适合目的的抗体平台，用于参与固有免疫。
MAbs. 2019 Jul;11(5):899-918. doi: 10.1080/19420862.2019.1616506. Epub 2019 Jun 7.
3
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.双特异性和三特异性免疫细胞衔接器在血液系统恶性肿瘤免疫治疗中的应用。
J Hematol Oncol. 2023 Jul 27;16(1):83. doi: 10.1186/s13045-023-01482-w.
4
Antibody-Dependent Cell-Mediated Cytotoxicity Through Natural Killer (NK) Cells: Unlocking NK Cells for Future Immunotherapy.抗体依赖的细胞介导的细胞毒性作用通过自然杀伤 (NK) 细胞：为未来的免疫疗法解锁 NK 细胞。
Curr Pharm Biotechnol. 2022;23(4):552-578. doi: 10.2174/1389201022666210820093608.
5
Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy.双特异性杀伤细胞接合器，对 NK 细胞表面的 CD16a 具有高亲和力和特异性，用于癌症免疫治疗。
Front Immunol. 2023 Jan 6;13:1039969. doi: 10.3389/fimmu.2022.1039969. eCollection 2022.
6
Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells.新型 NKG2D 导向双特异性抗体增强 NK 细胞和 T 细胞介导的抗体杀伤恶性 B 细胞。
Front Immunol. 2023 Oct 27;14:1227572. doi: 10.3389/fimmu.2023.1227572. eCollection 2023.
7
Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches.利用现有和新兴的免疫肿瘤学方法推进癌症治疗。
Front Oncol. 2017 Apr 18;7:64. doi: 10.3389/fonc.2017.00064. eCollection 2017.
8
Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer.NK 细胞衔接双特异性抗体治疗癌症的原则和临床现状。
Hum Vaccin Immunother. 2023 Aug;19(2):2256904. doi: 10.1080/21645515.2023.2256904. Epub 2023 Sep 29.
9
Incorporation of a Novel CD16-Specific Single-Domain Antibody into Multispecific Natural Killer Cell Engagers With Potent ADCC.将新型 CD16 特异性单域抗体与具有强大 ADCC 的多特异性自然杀伤细胞接合器结合。
Mol Pharm. 2021 Jun 7;18(6):2375-2384. doi: 10.1021/acs.molpharmaceut.1c00208. Epub 2021 May 17.
10
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.双特异性 T 细胞衔接器：一种用于血液系统恶性肿瘤治疗的新兴疗法。
J Hematol Oncol. 2021 May 3;14(1):75. doi: 10.1186/s13045-021-01084-4.
引用本文的文献
1
Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers.鉴定新型抗 CD16a 抗体克隆体，用于开发有效的自然杀伤细胞接合剂。
MAbs. 2024 Jan-Dec;16(1):2381261. doi: 10.1080/19420862.2024.2381261. Epub 2024 Jul 24.
2
Therapeutic antibodies for the prevention and treatment of cancer.用于癌症预防和治疗的治疗性抗体。
J Biomed Sci. 2024 Jan 12;31(1):6. doi: 10.1186/s12929-024-00996-w.
3
NKp46-specific single domain antibodies enable facile engineering of various potent NK cell engager formats.NKp46 特异性单域抗体可方便地工程化为各种有效的 NK 细胞衔接器形式。
Protein Sci. 2023 Mar;32(3):e4593. doi: 10.1002/pro.4593.
4
Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer.免疫治疗靶向激活自然杀伤细胞受体及其配体在癌症中的作用。
Clin Exp Immunol. 2022 Jul 22;209(1):22-32. doi: 10.1093/cei/uxac028.
5
The Biological Role and Therapeutic Potential of NK Cells in Hematological and Solid Tumors.自然杀伤细胞在血液系统恶性肿瘤和实体瘤中的生物学作用和治疗潜力。
Int J Mol Sci. 2021 Oct 21;22(21):11385. doi: 10.3390/ijms222111385.
6
Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors.新型 CD16A 特异性固有免疫细胞衔接子 AFM24 对表皮生长因子受体阳性肿瘤的临床前评估。
MAbs. 2021 Jan-Dec;13(1):1950264. doi: 10.1080/19420862.2021.1950264.
7
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma.一项 AFM13 联合帕博利珠单抗治疗复发或难治性霍奇金淋巴瘤患者的 1b 期研究。
Blood. 2020 Nov 19;136(21):2401-2409. doi: 10.1182/blood.2019004701.
8
Mechanisms of Resistance to NK Cell Immunotherapy.对自然杀伤细胞免疫疗法的耐药机制。
Cancers (Basel). 2020 Apr 7;12(4):893. doi: 10.3390/cancers12040893.
9
Peptides, Antibodies, Peptide Antibodies and More.肽、抗体、肽抗体及更多。
Int J Mol Sci. 2019 Dec 13;20(24):6289. doi: 10.3390/ijms20246289.
10
Phospholipase-Cγ1 Signaling Protein Down-Regulation by Oligoclonal-VHHs based Immuno-Liposome: A Potent Metastasis Deterrent in HER2 Positive Breast Cancer Cells.基于寡克隆VHH的免疫脂质体对磷脂酶Cγ1信号蛋白的下调：HER2阳性乳腺癌细胞中一种有效的转移抑制因素
Cell J. 2020 Apr;22(1):30-39. doi: 10.22074/cellj.2020.6704. Epub 2019 Sep 8.
本文引用的文献
1
Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer.PF-06671008的研发，一种高效的抗P-钙黏蛋白/抗CD3双特异性DART分子，具有延长的半衰期用于癌症治疗。
Antibodies (Basel). 2016 Mar 4;5(1):6. doi: 10.3390/antib5010006.
2
Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients.重链/轻链监测与多发性骨髓瘤患者的临床结局相关。
Leukemia. 2018 Feb;32(2):376-382. doi: 10.1038/leu.2017.209. Epub 2017 Jun 30.
3
A high-throughput platform for population reformatting and mammalian expression of phage display libraries to enable functional screening as full-length IgG.一种用于噬菌体展示文库的群体重排和哺乳动物表达的高通量平台，以实现全长IgG的功能筛选。
MAbs. 2017 Aug/Sep;9(6):996-1006. doi: 10.1080/19420862.2017.1337617. Epub 2017 Jun 14.
4
Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression.自然杀伤细胞的激活以及程序性死亡配体1/程序性死亡受体1（PD-L1/PD-1）轴的破坏：来那度胺阻断骨髓瘤进展的两种不同方式。
Oncotarget. 2017 Apr 4;8(14):24031-24044. doi: 10.18632/oncotarget.15234.
5
Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.用于开发治疗性双特异性抗体和新型支架的Fc工程
Front Immunol. 2017 Jan 26;8:38. doi: 10.3389/fimmu.2017.00038. eCollection 2017.
6
The making of bispecific antibodies.双特异性抗体的制备。
MAbs. 2017 Feb/Mar;9(2):182-212. doi: 10.1080/19420862.2016.1268307.
7
Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.双特异性抗体作为新概念和治疗策略的开发平台
Int J Mol Sci. 2016 Dec 28;18(1):48. doi: 10.3390/ijms18010048.
8
A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.一种新型的 BCMA/CD3 双特异性 T 细胞衔接子，用于治疗多发性骨髓瘤，可在体外和体内诱导选择性裂解。
Leukemia. 2017 Aug;31(8):1743-1751. doi: 10.1038/leu.2016.388. Epub 2016 Dec 27.
9
Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia.治疗性CD94/NKG2A阻断可改善慢性淋巴细胞白血病中的自然杀伤细胞功能障碍。
Oncoimmunology. 2016 Sep 9;5(10):e1226720. doi: 10.1080/2162402X.2016.1226720. eCollection 2016.
10
Identification of high-affinity anti-CD16A allotype-independent human antibody domains.高亲和力抗CD16A同种型非依赖性人抗体结构域的鉴定。
Exp Mol Pathol. 2016 Oct;101(2):281-289. doi: 10.1016/j.yexmp.2016.10.001. Epub 2016 Oct 3.
Zotero 插件